Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tatsuya Tamura,Nobuyuki Udagawa,Naoyuki Takahashi,Chisato Miyaura,Sakae Tanaka,Y Yamada,Yasuo Koishihara,Yoshiyuki Ohsugi,K Kumaki,Tetsuya Taga +9 more
TLDR
It is suggested that increased circulating or locally produced sIL-6R induces osteoclast formation in the presence of IL-6 mediated by a mechanism involving gp130, which may play an important physiological or pathological role in conditions associated with increased osteoclastic bone resorption.Abstract:
It has been reported that soluble interleukin (IL)-6 receptor (sIL-6R) is detected in the serum of healthy individuals and its level is increased in patients with multiple myeloma and human immunodeficiency virus infection. Although several reports have suggested that sIL-6R potentiates IL-6 action, its physiological role remains unclear. In this study, we examined the role of sIL-6R on osteoclast formation by IL-6, using a coculture of mouse osteoblasts and bone marrow cells. Neither recombinant mouse IL-6 (mIL-6) nor mouse sIL-6R (smIL-6R) induced osteoclast-like multinucleated cell (MNC) formation when they were added separately. In contrast, simultaneous treatment with mIL-6 and smIL-6R strikingly induced MNC formation. These MNCs satisfied major criteria of authentic osteoclasts, such as tartrate-resistant acid phosphatase (TRAP) activity, calcitonin receptors, and pit formation on dentine slices. The MNC formation induced by mIL-6 and smIL-6R was dose-dependently inhibited by adding monoclonal anti-mouse IL-6R antibody (MR16-1). It is likely that osteoblasts and osteoclast progenitors are capable of transducing a signal from a complex of IL-6 and sIL-6R through gp130, even though they may have no or a very small number of IL-6Rs. Factors such as IL-11, oncostatin M, and leukemia inhibitory factor, which are known to exert their functions through gp130 (the signal-transducing chain of IL-6R), also induced MNC formation in our coculture system. These results suggest that increased circulating or locally produced sIL-6R induces osteoclast formation in the presence of IL-6 mediated by a mechanism involving gp130. This may play an important physiological or pathological role in conditions associated with increased osteoclastic bone resorption.read more
Citations
More filters
Journal ArticleDOI
The pro- and anti-inflammatory properties of the cytokine interleukin-6
TL;DR: It turns out that regenerative or anti-inflammatory activities of interleukin-6 are mediated by classic signaling whereas pro-inflammatory responses of interLEukin -6 are rather mediated by trans-signaling.
Journal ArticleDOI
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
TL;DR: Osteoblasts/stromal cells can now be replaced with RANKL and M-CSF in dealing with the whole life of osteoclasts, and new ways to treat several metabolic bone diseases caused by abnormal osteoclast recruitment and functions will be established.
Journal ArticleDOI
Bone Marrow, Cytokines, and Bone Remodeling — Emerging Insights into the Pathophysiology of Osteoporosis
TL;DR: Changes in the numbers of bone cells, rather than changes in the activity of individual cells, form the pathogenetic basis of osteoporosis is a major advance in understanding the mechanism of this disease.
Journal ArticleDOI
Gp130 and the interleukin-6 family of cytokines
Tetsuya Taga,Tadamitsu Kishimoto +1 more
TL;DR: This paper reviews recent progress in the study of the interleukin-6 family of cytokines and gp130 and describes how the dimerization of gp130 leads to activation of associated cytoplasmic tyrosine kinases and subsequent modification of transcription factors.
Journal ArticleDOI
Cytokine signal transduction
TL;DR: Clinical Cancer Research is published monthly, one volume per year, by the American Association for Cancer Research, Inc.
References
More filters
Journal ArticleDOI
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Michio Kawano,Toshio Hirano,Tadashi Matsuda,Tetsuya Taga,Y Horii,Koji Iwato,Hideki Asaoku,Bo Tang,Osamu Tanabe,Hideo Tanaka,Atsushi Kuramoto,Tadamitsu Kishimoto +11 more
TL;DR: It is reported that myeloma cells freshly isolated from patients produce BSF-2 and express its receptors, direct evidence that an autocrine loop is operating in oncogenesis of human myelomas.
Journal ArticleDOI
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Tetsuya Taga,Masahiko Hibi,Y. Hirata,Katsuhiko Yamasaki,Kiyoshi Yasukawa,Tadashi Matsuda,Toshio Hirano,Tadamitsu Kishimoto +7 more
TL;DR: It is reported that an 80 kd single polypeptide chain (IL-6-R) is involved in IL-6 binding and that IL- 6 triggers the association of this receptor with a non-ligand-binding membrane glycoprotein, gp130, extracellularly and can provide the IL-7 signal.
Journal ArticleDOI
Increased osteoclast development after estrogen loss: mediation by interleukin-6
Robert L. Jilka,Giao Hangoc,Giuseppe Girasole,Giovanni Passeri,Daniel C. Williams,John S. Abrams,Brendan F. Boyce,Hal E. Broxmeyer,Stavros C. Manolagas +8 more
TL;DR: Estrogen loss results in an interleukin-6-mediated stimulation of osteoclastogenesis, which suggests a mechanism for the increased bone resorption in postmenopausal osteoporosis.
Journal Article
IL-6 is produced by osteoblasts and induces bone resorption.
Y. Ishimi,Chisato Miyaura,Cheng He Jin,Takuhiko Akatsu,Etsuko Abe,Y Nakamura,Akira Yamaguchi,Shusaku Yoshiki,Tadashi Matsuda,Toshio Hirano +9 more
TL;DR: Results indicate that IL-6 is also produced by osteoblasts, preferentially in response to local bone-resorbing agents, and it induces bone resorption both alone and in concert with other bone- RESORbing agents.
Journal ArticleDOI
Modulation of Osteoclast Differentiation
TL;DR: Osteotropic hormones such as 1α, 25-dihydroxyvitamin D3 [1α,25(OH)2D3], PTH, and calcitonin preferentially modulate the process of bone resorption to maintain bone remodeling.
Related Papers (5)
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
David L. Lacey,Emma Timms,Hong-Lin Tan,Michael J. Kelley,Colin R. Dunstan,Tim Burgess,Robin Elliott,Anne Colombero,Gary Elliott,S. Scully,Hailing Hsu,John K. Sullivan,Nessa Hawkins,E. Davy,C. Capparelli,Alana Eli,Yi-xin Qian,Steve Kaufman,Ildiko Sarosi,Victoria Shalhoub,Giorgio Senaldi,Jane Guo,John M. Delaney,William J. Boyle +23 more